HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$42.02
−1.68%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- $1.11
- Revenue estimate
- $274.5M
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- $1.28
- EPS estimate
- $0.96
- Revenue actual
- $261.3M
- Revenue estimate
- $250.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -13.5%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $48
- PT range
- $34 – $60
- Analysts
- 6
4 Buy2 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | $0.96 | $1.28 | Beat 33.89% | $261.3M |
| May 7, 2026 | $0.76 | $0.55 | Miss -27.63% | $215.4M |
| Feb 24, 2026 | $0.84 | $0.38 | Miss -54.76% | $243.8M |
| Nov 4, 2025 | $0.92 | $0.87 | Miss -5.43% | $239.5M |
| Apr 30, 2024 | $0.60 | $0.67 | Beat 11.67% | $154.6M |
| Feb 22, 2024 | $0.48 | $0.45 | Miss -6.25% | $168.4M |
| Oct 31, 2023 | $0.65 | $0.75 | Beat 15.38% | $160.3M |
| May 2, 2023 | $0.44 | $0.48 | Beat 9.09% | $119.1M |
| Feb 21, 2023 | $0.58 | $0.79 | Beat 36.21% | $128.3M |
| Nov 1, 2022 | $0.10 | $0.95 | Beat 850.00% | $117.2M |
| Aug 2, 2022 | $0.40 | $0.57 | Beat 42.50% | $107.0M |
| May 3, 2022 | $0.25 | $0.51 | Beat 104.00% | $85.3M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026